GlassScriptPhysician profile
Jaime Buhmann
NPI 1700609948
$704.01
in general payments reported to CMS, 2019-2025
17 companies · $687 in 2025
The $687 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $17.19 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $115.92 | 2025 | Voquezna |
| Amgen INC. | $86.54 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $76.32 | 2025 | |
| Ardelyx, INC. | $73.24 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $51.43 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $43.46 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.84 | 2025 | Relistor |
| Abbvie INC. | $38.58 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $36.11 | 2025 | Belbuca |
| Idorsia Pharmaceuticals US INC | $25.58 | 2025 | Quviviq |
| Exact Sciences Corporation | $20.25 | 2025 | The Cologuard Plus Collection Kit |
| Valinor Pharma, LLC | $20.10 | 2025 | Movantik |
| Viatris Specialty LLC | $17.36 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $16.08 | 2025 | Farxiga |
| Lilly USA, LLC | $15.71 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $14.59 | 2025 | |
| Sumitomo Pharma America, INC. | $13.90 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Buhmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.